XBKK
MEGA
Market cap814mUSD
Nov 12, Last price
29.75THB
Name
Mega Lifesciences PCL
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Mega Lifesciences Public Company Limited, together with its subsidiaries, manufactures, markets, and sells health food supplements, prescription pharmaceutical products, over-the-counter (OTC) products, herbal products, vitamins, and fast moving consumer goods. The company operates through Brands, Distribution, and Original Equipment Manufacture segments. It provides various complementary medicines for bone and joint, children, diabetic, heart, herbal, liver and digestive, skin, slimming, and well-being care, as well as men's and women's care products and sports supplements; gastrointestinal and pain care OTC medicines; and prescription medicines in the areas of iron supplement, anticoagulant, diabetology, cardiology, dermatology, gastroenterology, neurology, pain, osteoporosis, respiratory, urology, oncology, and nephrology. The company also offers logistical and marketing services for the sale of goods manufactured by third parties. In addition, the company engages in the operation of wellness center; and software design, development, and other services business. It operates in the Asia Pacific, the Middle East, Africa, and the Commonwealth of Independent States. The company was incorporated in 1982 and is headquartered in Bangkok, Thailand. Mega Lifesciences Public Company Limited is a subsidiary of Unistretch Limited.
Valuation
Title THB in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||